GNRH1 and central precocious puberty: Soriano-Guillén L et al. estimated that the global incidence rate of CPP with GnRH agonists treatment was 5.66 cases per million person-years at risk, with an annual incidence ranging between 0.002 and 0.107 per 10,000 [28].